Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research

Rhea-AI Summary

Illumina (NASDAQ:ILMN) and SPT Labtech launched fireflyGO, a benchtop automation platform for liquid handling and library preparation in targeted oncology research. Integrated with the MiSeq i100 Series, it automates NGS workflows and supports Pillar Biosciences oncoReveal panels for solid tumor and lymphoid malignancy research.

Illumina is also expanding its oncoReveal portfolio with the Nexus 21 Gene Panel and an 84‑gene Lymphoid Panel, both available worldwide and focused on rapid, simplified genomic characterization of multiple cancer types.

Positive

• Launch of fireflyGO automation platform for NGS oncology workflows
• Integration of fireflyGO with MiSeq i100 Series sequencers
• Reduced manual touchpoints and lab staffing needs in library prep
• Automation support for Pillar Biosciences oncoReveal targeted panels
• Expansion of oncoReveal Nexus 21 Gene Panel for multiple solid and hematologic cancers
• Global availability of 84-gene oncoReveal Lymphoid Panel for lymphoid malignancies

Negative

• None.

News Market Reaction – ILMN

+5.68%

10 alerts

+5.68% Session close to close

$23.82B Market Cap

0.2x Rel. Volume

In the May 28 session, ILMN gained 5.68%, reflecting a notable positive market reaction. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with Ill...

Analysis

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with Illumina’s history of constructive responses to product and workflow launches, such as prior DRAGEN and pediatric genomics announcements that saw gains of up to 7.13%. However, investors have also seen softer reactions to governance and ESG updates. With shares already trading above the $121.62 200-day MA and near the $155.529 52-week high, past patterns suggest enthusiasm can moderate after initial product-driven optimism.

Key Figures

Nexus gene panel size: 21 genes Lymphoid panel size: 84 genes ASCO booth: #33106 +1 more

4 metrics

Nexus gene panel size 21 genes oncoReveal Nexus 21 Gene Panel for solid tumors and hematologic malignancies

Lymphoid panel size 84 genes oncoReveal Lymphoid DNA panel spanning B-cell, T-cell and lymphoblastic markers

ASCO booth #33106 Illumina booth location at ASCO Annual Meeting in Chicago

ASCO meeting dates May 29–June 2 fireflyGO and oncoReveal panels showcased at ASCO Annual Meeting

Historical Context

5 past events · Latest: May 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 21	Board appointment	Positive	-0.3%	Former Labcorp executive elected to Illumina’s board to bolster clinical genomics.
May 19	ESG/report	Positive	-0.8%	Corporate Responsibility Report highlighting access to genomics and sustainability progress.
Apr 30	Earnings results	Positive	+7.1%	Q1 FY2026 beat with higher revenue, margins, cash flow, and guidance raise.
Apr 16	Product launch	Positive	+0.3%	Launch of DRAGEN v4.5 with improved variant calling and oncology capabilities.
Apr 14	Data partnership	Positive	+2.6%	Partnership to analyze 100,000 pediatric genomes using cloud-based DRAGEN platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Product, partnership, and data launches have generally seen positive price reactions, while governance and ESG-style updates have had muted or negative next-day moves.

Recent Company History

Over the last few months, Illumina reported stronger Q1 FY2026 financials with revenue of $1.09B and a $1.5B share repurchase authorization, which was followed by a 7.13% gain. Product and data-platform launches such as DRAGEN v4.5 and the D3b pediatric genomics partnership also coincided with positive moves. In contrast, board and corporate responsibility updates saw slight declines. Today’s automation and oncology workflow news fits the pattern of product-centric catalysts supporting the clinical genomics strategy.

Key Terms

next-generation sequencing, ngs, library preparation, liquid handling, +4 more

8 terms

next-generation sequencing medical

"By making next-generation sequencing (NGS) more accessible, scalable, and easier to adopt"

Next-generation sequencing is a set of laboratory techniques that read large amounts of DNA or RNA quickly and cheaply by processing millions of short genetic fragments in parallel, rather than one at a time. For investors, it matters because faster, lower-cost genetic data powers drug discovery, diagnostic tests and personalized medicine, creating scalable revenue opportunities and competitive advantages for companies that own the technology or services.

ngs medical

"This solution also enables automation capabilities for a growing menu of NGS panels"

A laboratory method that reads large amounts of DNA or RNA quickly to identify genetic differences, mutations, or microbes, similar to scanning many pages of a book at once to find important words. Investors care because it drives diagnostics, drug discovery and personalized treatments, can create recurring revenue from testing services and instruments, and influences regulatory approvals, partnerships and market value in biotech and healthcare companies.

library preparation technical

"a new benchtop liquid handling and library preparation solution that brings automation"

Library preparation is the laboratory process that converts samples of DNA or RNA into a standardized format that sequencing machines can read, like turning raw ingredients into a set of prepped dishes ready for a chef. Investors should care because the speed, cost, and reliability of this step affect how quickly and cheaply genetic tests, drug development studies, or diagnostic products can move from research into commercial use, influencing product timelines and margins.

liquid handling technical

"a new benchtop liquid handling and library preparation solution that brings automation"

Liquid handling is the set of tools and processes used in labs to move, measure and mix small volumes of liquids—think pipettes, automated dispensers and the robots that replace repetitive manual pouring. Investors care because it is a foundational part of research and diagnostics infrastructure: better liquid handling increases speed, accuracy and reproducibility of tests and experiments, which drives demand for equipment, consumables and software that generate recurring revenue.

solid tumor medical

"panels and workflows focused on solid tumor and hematologic malignancies and lymphoid conditions"

A solid tumor is a localized mass of abnormal cells that forms in an organ or tissue, like a lump in the lung, liver or breast, as opposed to cancers that circulate in the blood. For investors it matters because solid tumors determine how treatments are developed, tested and approved — like choosing tools for a visible fortress versus scattered targets — affecting trial design, potential market size and regulatory risk.

hematologic malignancies medical

"solid tumor and hematologic malignancies and lymphoid conditions to enable rapid"

Hematologic malignancies are types of cancers that start in the blood or the organs responsible for blood production, like the bone marrow and lymph nodes. They matter because they can disrupt normal blood functions, leading to issues like weakness, infections, or abnormal growths, and often require specialized treatments.

lymphoid malignancies medical

"to help genomically characterize lymphoid malignancies including CLL/SLL, WM/LPL, FL, MCL"

Lymphoid malignancies are cancers that start in the immune system’s lymph cells, which normally help fight infection; examples include various types of lymphoma and leukemia. For investors, they matter because developing treatments, diagnostic tests, or care services for these diseases can drive large clinical trial programs, regulatory decisions, market demand, and long-term revenue or liability—think of a new drug as a high-stakes product that can reshape a company’s prospects if it succeeds or fails.

dna panel medical

"The oncoReveal Lymphoid Panel is an 84 gene DNA panel spanning high-value"

A DNA panel is a laboratory test that examines a set of specific genes or genetic markers tied to a particular health condition, trait, or drug response. Think of it like checking a focused list of ingredients on a recipe card rather than reading the entire cookbook; it gives targeted information faster and cheaper than sequencing a whole genome. Investors care because panels drive demand for diagnostic services, affect regulatory approvals, and can change a company’s revenue prospects when used for screening, diagnosis, or guiding treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Automating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panels

SAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and SPT Labtech today introduced the fireflyGO automation platform, a new benchtop liquid handling and library preparation solution that brings automation, speed, and simplicity to targeted oncology research. Integrated with the MiSeq™ i100 Series, fireflyGO helps laboratories streamline workflows, expand application flexibility, and unlock genomic insights with greater efficiency. By making next-generation sequencing (NGS) more accessible, scalable, and easier to adopt, Illumina continues to accelerate the shift toward genomics in cancer testing and as a standard of care in oncology.

"Illumina is delivering end-to-end workflow solutions that help customers across the healthcare and research ecosystem make genomic testing more efficient and accessible," said Sandy Ottensmann, vice president and general manager of Global Clinical Solutions. "The fireflyGO platform paired with Illumina MiSeq i100 sequencers and Pillar Biosciences targeted panel assays advances research and serves as a catalyst for broadening genomic testing in cancer, driving shorter turnaround times leading to fast results."

Simplified automation for targeted oncology workflows

The fireflyGO platform automates library preparation and liquid handling as part of a streamlined workflow for sequencing and analysis on the MiSeq i100 Series. The workflow reduces manual touchpoints, providing higher reproducibility and reliability while reducing laboratory staffing needs. This solution also enables automation capabilities for a growing menu of NGS panels developed by Pillar Biosciences, supporting Illumina's targeted oncology research portfolio.

"Simplifying oncology workflows improves research and access to testing with the goal of delivering treatment faster. Our collaboration with Illumina reflects a shared focus on enabling efficient and accessible genomics workflows," said Rob Walton, chief executive officer at SPT Labtech. "By combining SPT Labtech's expertise in automation with Illumina's global strength in sequencing, we are positioned to help labs adopt genomics workflows."

Expanding Illumina's oncology research portfolio

Illumina is also expanding its Pillar Biosciences oncoReveal® targeted research portfolio with panels and workflows focused on solid tumor and hematologic malignancies and lymphoid conditions to enable rapid and simplified results:

• The oncoReveal® Nexus 21 Gene Panel offers rapid solid tumor and hematological malignancy sequencing for multiple cancer types including NSCLC, endometrial, AML, B-Cell Lymphoma and MPN.
• The oncoReveal® Lymphoid Panel is an 84 gene DNA panel spanning high-value B-cell, T-cell, and lymphoblastic markers including full coverage of BTK to help genomically characterize lymphoid malignancies including CLL/SLL, WM/LPL, FL, MCL, DLBCL/LBCL, HCL, and multiple T-cell entities.

These oncoReveal panels are currently available to customers worldwide.

Expanding access to NGS in oncology clinical research

The fireflyGO automation liquid handler, together with Illumina sequencing platforms and partner-developed content like Pillar oncoReveal panels, reinforces Illumina's mission to improve human health by unlocking the power of the genome.

To see and learn more about the fireflyGO platform with the MiSeq i100 and Pillar oncoReveal panels, visit the Illumina booth, #33106, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29 through June 2.

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, manufacturing, and launching new products and services;  (ii) our and our partners' ability to deploy new products, services, and applications, and to expand the markets for genomics-related products and services; and (iii) the challenges associated with multiparty collaborations, including our reliance on the performance of such partners,  together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts

Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com

Media:
Christine Douglass
PR@illumina.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-and-spt-labtech-unveil-fireflygo-enabling-faster-simpler-targeted-oncology-research-302784759.html

SOURCE Illumina, Inc.

FAQ

What is Illumina's fireflyGO platform and how does it support ILMN oncology research?

fireflyGO is a benchtop automation platform that handles liquid handling and library preparation for targeted oncology research. According to Illumina, it integrates with MiSeq i100 sequencers to streamline NGS workflows, reduce manual steps, and improve efficiency in cancer genomics labs.

How does fireflyGO integrate with the MiSeq i100 Series for ILMN sequencing workflows?

fireflyGO is designed to work with the MiSeq i100 Series as part of a streamlined sequencing and analysis workflow. According to Illumina, this integration automates library preparation, cuts manual touchpoints, and supports efficient targeted oncology research using partner-developed NGS panels.

What are Pillar Biosciences oncoReveal panels used with Illumina (ILMN) fireflyGO?

Pillar Biosciences oncoReveal panels are targeted oncology research assays for solid tumors and hematologic malignancies. According to Illumina, fireflyGO automation supports these panels, enabling simplified NGS workflows for cancer genomics using Illumina sequencing platforms in research laboratories worldwide.

What cancers does the oncoReveal Nexus 21 Gene Panel from Illumina and Pillar target?

The oncoReveal Nexus 21 Gene Panel supports rapid sequencing for NSCLC, endometrial cancer, AML, B-cell lymphoma, and MPN. According to Illumina, it enables targeted solid tumor and hematologic malignancy research across multiple cancer types within a unified NGS workflow.

What does the oncoReveal Lymphoid Panel offer for ILMN lymphoid malignancy research?

The oncoReveal Lymphoid Panel is an 84-gene DNA panel covering key B-cell, T-cell, and lymphoblastic markers, including full BTK coverage. According to Illumina, it helps characterize lymphoid malignancies such as CLL/SLL, WM/LPL, FL, MCL, DLBCL/LBCL, HCL, and various T-cell entities.

Is the Illumina oncoReveal targeted oncology research portfolio available globally for ILMN users?

Yes, Illumina states that the oncoReveal Nexus 21 Gene Panel and Lymphoid Panel are available to customers worldwide. According to Illumina, these targeted oncology research panels work with fireflyGO automation and MiSeq i100 sequencers to support accessible cancer genomics research.

How might fireflyGO impact turnaround times for targeted oncology NGS workflows using ILMN technology?

fireflyGO aims to shorten turnaround times by automating liquid handling and library preparation in NGS workflows. According to Illumina, reduced manual touchpoints and integrated sequencing on MiSeq i100 platforms can support faster, more reproducible results for targeted oncology research applications.